Presentations


Xbrane Company Presentation April 2025

Xbrane Company Presentation

Press Releases

14 Apr 2025

Announcement from extra general meeting in Xbrane Biopharma AB

02 Apr 2025

NOTICE OF ANNUAL GENERAL MEETING IN XBRANE BIOPHARMA AB

31 Mar 2025

XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2024

20 Mar 2025

Notice of Extra General Meeting in Xbrane Biopharma AB

20 Mar 2025

Xbrane has entered into an agreement to sell XB003 (Cimzia biosimilar candidate) and parts of its organization to Alvotech for a total consideration of SEK 275 million

20 Feb 2025

Xbrane Biopharma releases Year-end Report 2024

17 Feb 2025

Invitation to presentation of Xbrane Biopharma’s Year-end report 2024 on February 20, 2025

31 Jan 2025

The number of shares and votes in Xbrane has changed as a result of 2,706,898 shares being issued during January through the exercise of warrants in December 2024.

09 Jan 2025

Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.

Financial Reports

31 May 2023

Interim Report January – March 2023

16 May 2024

Interim Report January – March 2024

28 Aug 2024

Interim Report January – June 2024

24 Oct 2024

Interim report January – September 2024

31 Dec 2024

Year-end Report 2024

Financial Calendar

05 May 2025

Annual General Meeting 2025

08 May 2025

Interim report January- March 2025

27 Aug 2025

Interim report January – June 2025

24 Oct 2025

Interim report January – September 2025

Contact Investor Relations

Jane Benyamin, Interim CFO & Head of Investor Relation

Presentations and media


Presentation at Aktiespararna, Life Science

April, 2025

Presenter:
Martin Åmark, CEO

Presentation at Stora Aktiedagarna

Mars, 2025

Presenter:
Martin Åmark, CEO

Presentation at Stora Aktiedagarna

Mars, 2024

Presenter:
Siavash Bashiri, COO & Head of Biosimilars

PRESENTATION AT PARETO HELTHCARE CONFERENCE

September 3, 2020

Presentation at LSX Nordic Congress

August 29, 2019

Presentation at BioStock Live

March 20, 2019